TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dental and Medical Office Internet/Intranet Motivational Enhancement Therapy to Reduce Teen Tobacco, Alcohol, and Drug Use
Brief Summary: The purpose of the project is to improve adolescent behavioral counseling services in healthcare settings with a new Internet/Intranet-based Motivational Enhancement Therapy (iMET) intervention that targets the use of tobacco, alcohol, and other drugs.


Options:
A: Arm Label: study groups; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): study groups | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): control group
B: Arm Label: 1; Type: N/A; Interventions: Behavioral: Standard Care only | Arm Label: 2; Type: N/A; Interventions: Behavioral: Dental Hygienist provided counseling + Brief Questionnaire | Arm Label: 3; Type: N/A; Interventions: Behavioral: Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire | Intervention Type: BEHAVIORAL; Name: Standard Care only; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Dental Hygienist provided counseling + Brief Questionnaire; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire; Assigned to Arm(s): 3
C: Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: iMET; Type: EXPERIMENTAL; Interventions: Behavioral: iMET | Arm Label: iMET/TE; Type: EXPERIMENTAL; Interventions: Behavioral: iMET/TE | Intervention Type: BEHAVIORAL; Name: iMET; Assigned to Arm(s): iMET | Intervention Type: BEHAVIORAL; Name: iMET/TE; Assigned to Arm(s): iMET/TE
D: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablet is made of lactose | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo tablet is made of lactose; Assigned to Arm(s): control group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Prevalence of Low Back Symptoms in a Finnish Forestry Company - Effectiveness of Primary Care Interventions for Non-acute Low Back Symptoms in Occupational Health. Two Separate Randomised Controlled Trials (RCT) of Various Levels.
Brief Summary: The purpose of this study is:

* Epidemiological part: characteristics of low back pain patients from a forestry company in Finland. Data is collected from occupational health databases and self administered questionnaires.
* Intervention: To determine the effectiveness and cost-effectiveness of several different interventions in subacute low back pain (LBP) patients in occupational health (OH).


Options:
A: Arm Label: BB; Type: ACTIVE_COMPARATOR; Interventions: Other: Mild, Other: Mild vs. NC | Arm Label: BB+A; Type: EXPERIMENTAL; Interventions: Other: Moderate, Other: Mild, Other: Mild vs. NC, Other: Moderate vs. NC | Arm Label: DBC; Type: EXPERIMENTAL; Interventions: Other: Moderate, Other: Moderate vs. NC | Arm Label: PMU; Type: EXPERIMENTAL; Interventions: Other: Moderate, Other: Moderate vs. NC | Arm Label: NC; Type: PLACEBO_COMPARATOR; Interventions: Other: Mild vs. NC, Other: Moderate vs. NC | Intervention Type: OTHER; Name: Moderate; Assigned to Arm(s): BB+A, DBC, PMU | Intervention Type: OTHER; Name: Mild; Assigned to Arm(s): BB, BB+A | Intervention Type: OTHER; Name: Mild vs. NC; Assigned to Arm(s): BB, BB+A, NC | Intervention Type: OTHER; Name: Moderate vs. NC; Assigned to Arm(s): BB+A, DBC, NC, PMU
B: Intervention Type: BEHAVIORAL; Name: Fear-reducing Information; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Symptom-based exercise; Assigned to Arm(s): N/A
C: Arm Label: Motor Control Exercise Plus Patient Education; Type: EXPERIMENTAL; Interventions: Behavioral: Motor Control Exercise, Behavioral: Patient Education | Arm Label: Motor Control Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Motor Control Exercise | Arm Label: Patient Education; Type: EXPERIMENTAL; Interventions: Behavioral: Patient Education | Intervention Type: BEHAVIORAL; Name: Motor Control Exercise; Assigned to Arm(s): Motor Control Exercise, Motor Control Exercise Plus Patient Education | Intervention Type: BEHAVIORAL; Name: Patient Education; Assigned to Arm(s): Motor Control Exercise Plus Patient Education, Patient Education
D: Intervention Type: PROCEDURE; Name: High intensity motor control exercise (deadlift); Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Low intensity motor control exercise; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Prevalence of Low Back Symptoms in a Finnish Forestry Company - Effectiveness of Primary Care Interventions for Non-acute Low Back Symptoms in Occupational Health. Two Separate Randomised Controlled Trials (RCT) of Various Levels.
Brief Summary: The purpose of this study is:

* Epidemiological part: characteristics of low back pain patients from a forestry company in Finland. Data is collected from occupational health databases and self administered questionnaires.
* Intervention: To determine the effectiveness and cost-effectiveness of several different interventions in subacute low back pain (LBP) patients in occupational health (OH).


Options:
A: Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Usual care | Arm Label: Integrative care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Integrative care | Intervention Type: PROCEDURE; Name: Integrative care; Assigned to Arm(s): Integrative care | Intervention Type: PROCEDURE; Name: Usual care; Assigned to Arm(s): Usual care
B: Intervention Type: BEHAVIORAL; Name: Fear-reducing Information; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Symptom-based exercise; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: General health talk, Behavioral: Handout of The Back Book, Behavioral: Back exercise | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Handout of The Back Book, Behavioral: Back exercise | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Back exercise | Intervention Type: BEHAVIORAL; Name: General health talk; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Handout of The Back Book; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Back exercise; Assigned to Arm(s): 1, 2, 3
D: Arm Label: BB; Type: ACTIVE_COMPARATOR; Interventions: Other: Mild, Other: Mild vs. NC | Arm Label: BB+A; Type: EXPERIMENTAL; Interventions: Other: Moderate, Other: Mild, Other: Mild vs. NC, Other: Moderate vs. NC | Arm Label: DBC; Type: EXPERIMENTAL; Interventions: Other: Moderate, Other: Moderate vs. NC | Arm Label: PMU; Type: EXPERIMENTAL; Interventions: Other: Moderate, Other: Moderate vs. NC | Arm Label: NC; Type: PLACEBO_COMPARATOR; Interventions: Other: Mild vs. NC, Other: Moderate vs. NC | Intervention Type: OTHER; Name: Moderate; Assigned to Arm(s): BB+A, DBC, PMU | Intervention Type: OTHER; Name: Mild; Assigned to Arm(s): BB, BB+A | Intervention Type: OTHER; Name: Mild vs. NC; Assigned to Arm(s): BB, BB+A, NC | Intervention Type: OTHER; Name: Moderate vs. NC; Assigned to Arm(s): BB+A, DBC, NC, PMU

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Corticoids in Severe Community-acquired Pneumonia
Brief Summary: The purpose of this study is to assess the efficacy of glucocorticoids as an adjuvant therapy in patients with severe community-acquired pneumonia (CAP) (Fine V). The hypothesis of the study is that glucocorticoids can modulate the excessive inflammatory response in patients with severe CAP without any significant side effects, showing a benefit in the percentage of non-response to the empiric antimicrobial treatment.


Options:
A: Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): N/A
B: Arm Label: methylprednisolone; Type: EXPERIMENTAL; Interventions: Drug: methylprednisolone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): methylprednisolone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: dexamethasone | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): 1, 2
D: Arm Label: Prednisone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prednisone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Prednisone | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Placebo, Prednisone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Corticoids in Severe Community-acquired Pneumonia
Brief Summary: The purpose of this study is to assess the efficacy of glucocorticoids as an adjuvant therapy in patients with severe community-acquired pneumonia (CAP) (Fine V). The hypothesis of the study is that glucocorticoids can modulate the excessive inflammatory response in patients with severe CAP without any significant side effects, showing a benefit in the percentage of non-response to the empiric antimicrobial treatment.


Options:
A: Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone, Placebo
B: Arm Label: methylprednisolone; Type: EXPERIMENTAL; Interventions: Drug: methylprednisolone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): methylprednisolone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: RIPC; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote Ischemic Preconditioning | Arm Label: CONTROL; Type: SHAM_COMPARATOR; Interventions: Procedure: Control/sham procedure (blood pressure cuff) | Intervention Type: PROCEDURE; Name: Remote Ischemic Preconditioning; Assigned to Arm(s): RIPC | Intervention Type: PROCEDURE; Name: Control/sham procedure (blood pressure cuff); Assigned to Arm(s): CONTROL
D: Arm Label: Inhalational anesthetic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Inhalational anesthetic | Arm Label: Intravenous anesthetic, propofol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous anesthetic, propofol | Intervention Type: DRUG; Name: Inhalational anesthetic; Assigned to Arm(s): Inhalational anesthetic | Intervention Type: DRUG; Name: Intravenous anesthetic, propofol; Assigned to Arm(s): Intravenous anesthetic, propofol

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Corticoids in Severe Community-acquired Pneumonia
Brief Summary: The purpose of this study is to assess the efficacy of glucocorticoids as an adjuvant therapy in patients with severe community-acquired pneumonia (CAP) (Fine V). The hypothesis of the study is that glucocorticoids can modulate the excessive inflammatory response in patients with severe CAP without any significant side effects, showing a benefit in the percentage of non-response to the empiric antimicrobial treatment.


Options:
A: Arm Label: Hydrocortisone and fludrocortisone; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone Fludrocortisone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Controlled; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Hydrocortisone Fludrocortisone; Assigned to Arm(s): Hydrocortisone and fludrocortisone
B: Arm Label: Hydrocortisone; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): Hydrocortisone
C: Intervention Type: DRUG; Name: intensive insulin therapy to maintain normoglycemia; Assigned to Arm(s): N/A
D: Arm Label: methylprednisolone; Type: EXPERIMENTAL; Interventions: Drug: methylprednisolone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): methylprednisolone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Corticoids in Severe Community-acquired Pneumonia
Brief Summary: The purpose of this study is to assess the efficacy of glucocorticoids as an adjuvant therapy in patients with severe community-acquired pneumonia (CAP) (Fine V). The hypothesis of the study is that glucocorticoids can modulate the excessive inflammatory response in patients with severe CAP without any significant side effects, showing a benefit in the percentage of non-response to the empiric antimicrobial treatment.


Options:
A: Arm Label: methylprednisolone; Type: EXPERIMENTAL; Interventions: Drug: methylprednisolone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): methylprednisolone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydrocortisone | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: hydrocortisone, Drug: fludrocortisone | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: recombinant human insulin, Drug: hydrocortisone | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: recombinant human insulin, Drug: hydrocortisone, Drug: fludrocortisone | Intervention Type: DRUG; Name: recombinant human insulin; Assigned to Arm(s): 3, 4 | Intervention Type: DRUG; Name: hydrocortisone; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: fludrocortisone; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): 1
C: Arm Label: Prednisone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prednisone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Prednisone | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Placebo, Prednisone
D: Intervention Type: DRUG; Name: hydrocortisone 200 mg/day; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
Brief Summary: Research studies have shown a strong association between cancer and blood clots in the veins (also known as deep vein thrombosis). These blood clots can flow to the lungs (pulmonary embolism) which in severe cases may be life threatening. The purpose of this research study is to see if enoxaparin is effective in preventing blood clots in the veins in participants who have cancer of the pancreas, colorectal, non-small cell lung, ovary, or gastric and also have high levels of tissue factor bearing microparticles in their blood (TFMP). TFMP are small particles that are generated from different types of blood cells in the body. In people who have cancer, TFMP are thought to be generated from cancer cells and may represent a risk factor for deep vein thrombosis. Enoxaparin has been used to prevent formation of blood clots in patients after abdominal or orthopedic surgery and in patients who suffer from a severe medical illness. Based on these studies, we are investigating to see if it prevents thrombosis in people with certain types of cancer.


Options:
A: Arm Label: Group 1: Dalteparin; Type: EXPERIMENTAL; Interventions: Drug: Dalteparin | Arm Label: Group 2: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Group 1: Dalteparin
B: Arm Label: High TFMP: Enoxaparin; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparin | Arm Label: High TFMP: Observation; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low TFMP: Observation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): High TFMP: Enoxaparin
C: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: cisplatin + docetaxel | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: cisplatin + docetaxel + enoxaparin | Intervention Type: DRUG; Name: cisplatin + docetaxel; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: cisplatin + docetaxel + enoxaparin; Assigned to Arm(s): Arm B
D: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
Brief Summary: Research studies have shown a strong association between cancer and blood clots in the veins (also known as deep vein thrombosis). These blood clots can flow to the lungs (pulmonary embolism) which in severe cases may be life threatening. The purpose of this research study is to see if enoxaparin is effective in preventing blood clots in the veins in participants who have cancer of the pancreas, colorectal, non-small cell lung, ovary, or gastric and also have high levels of tissue factor bearing microparticles in their blood (TFMP). TFMP are small particles that are generated from different types of blood cells in the body. In people who have cancer, TFMP are thought to be generated from cancer cells and may represent a risk factor for deep vein thrombosis. Enoxaparin has been used to prevent formation of blood clots in patients after abdominal or orthopedic surgery and in patients who suffer from a severe medical illness. Based on these studies, we are investigating to see if it prevents thrombosis in people with certain types of cancer.


Options:
A: Arm Label: saline solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline solution (placebo) | Arm Label: nadroparin calcium; Type: EXPERIMENTAL; Interventions: Drug: Nadroparin calcium | Intervention Type: DRUG; Name: Nadroparin calcium; Assigned to Arm(s): nadroparin calcium | Intervention Type: DRUG; Name: saline solution (placebo); Assigned to Arm(s): saline solution
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: enoxaparin, Drug: chemotherapy with LMWH - enoxaparin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: only chemotherapy | Intervention Type: DRUG; Name: enoxaparin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: chemotherapy with LMWH - enoxaparin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: only chemotherapy; Assigned to Arm(s): B
C: Arm Label: High TFMP: Enoxaparin; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparin | Arm Label: High TFMP: Observation; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low TFMP: Observation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): High TFMP: Enoxaparin
D: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Computer-aided Diagnosis of Endoscopic Ultrasound Elastography Used in the Differentiation of Focal Pancreatic Masses
Brief Summary: The aim of the study is to assess elastography during EUS examinations of focal pancreatic masses, and to consequently differentiate benign versus malignant pancreatic masses in a prospective multi-center design.


Options:
A: Arm Label: EUS-FNB with 25-gauge; Type: EXPERIMENTAL; Interventions: Device: EUS-FNB with 25-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland) | Intervention Type: DEVICE; Name: EUS-FNB with 25-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland); Assigned to Arm(s): EUS-FNB with 25-gauge
B: Arm Label: EUS FNA with 2 passes; Type: ACTIVE_COMPARATOR; Interventions: Procedure: EUS FNA with 2 passes | Arm Label: EUS FNA with 4 passes; Type: ACTIVE_COMPARATOR; Interventions: Procedure: EUS FNA with 4 passes | Intervention Type: PROCEDURE; Name: EUS FNA with 2 passes; Assigned to Arm(s): EUS FNA with 2 passes | Intervention Type: PROCEDURE; Name: EUS FNA with 4 passes; Assigned to Arm(s): EUS FNA with 4 passes
C: Arm Label: Pancreatic adenocarcinoma; Type: N/A; Interventions: N/A | Arm Label: Chronic pancreatitis; Type: N/A; Interventions: N/A
D: Arm Label: Lymph nodes, pancreatic masses & cysts; Type: OTHER; Interventions: Procedure: EUS-FNA, Device: nCLE | Intervention Type: PROCEDURE; Name: EUS-FNA; Assigned to Arm(s): Lymph nodes, pancreatic masses & cysts | Intervention Type: DEVICE; Name: nCLE; Assigned to Arm(s): Lymph nodes, pancreatic masses & cysts

Answer: C